Evaluating the costs, benefits and cost-effectiveness of multi-pathogen point-of-care tests for sexually transmitted infections
Modelling how point-of-care tests can enable personalised treatment for resistant gonorrhoea infections
Estimating the clinical impact and costs of implementing a point of care test for influenza A/B and respiratory syncytial virus on an acute paediatric hospital inpatient ward
A rapid influenza test in hospitals could avoid unnecessary paediatric isolation bed days and save costs
Performance of a novel point-of-care molecular assay for the detection of Influenza A, B and RSV in children
Thinking critically about the value and cost of drugs: managing patients with invasive fungal disease
There is a temptation to switch to cheaper generic antiretroviral drugs compared to fixed-dose combination therapy for HIV patients in the interests of cost savings. However, in our analysis we found that there were no costs saved when including all patient care including drugs, additional clinic visits and monitoring. We also found that switching may cause confusion for some patients, risking loss of adherence. This evidence can help commissioners make better policy decisions about drug provision.